VA Salt Lake City Health Care System, Salt Lake City, UT
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, United States24 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combining a Smartphone App With Medications to Manage Heavy Drinking | Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorder | Recruiting | Not applicable | 2026-10-07 | NCT06303778 | |
| CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA) | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-10-07 | NCT05996328 | |
| Comparing the Safety and Efficacy of Apixaban and Rivaroxaban | Arrhythmias, Cardiac, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 4 | 2026-09-23 | NCT06953726 | |
| Geri Pride: Feasibility Pilot of a Group Intervention for Older Veterans | Aging; Health Disparate Minority and Vulnerable Populations; Social Determinants of Health; Veterans | Not yet recruiting | Not applicable | 2026-09-21 | NCT07831759 | |
| Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorder | Recruiting | Phase 3 | 2026-09-21 | NCT07218354 | |
| A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 4 | 2026-09-10 | NCT04375033 | |
| Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Not applicable | 2026-09-04 | NCT01239082 | |
| Physical Activity Modifies Exercise Responsiveness | Multimorbidity | Not yet recruiting | Not applicable | 2026-08-28 | NCT07792967 | |
| Vascular Effects of SGLT2i in Non-diabetic CKD | Non-diabetic Chronic Kidney Disease | Not yet recruiting | Phase 2 | 2026-08-20 | NCT07060417 | |
| Long-term COVID and Rehabilitation | COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, long COVID-19, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Not applicable | 2026-07-30 | NCT05373043 | |
| Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, overactive bladder, parkinsonian disorder, synucleinopathy, urinary bladder disorder, urinary system disorder | Not yet recruiting | Phase 4 | 2026-07-22 | NCT07187466 | |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | Chronic Disease, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Fibrosis, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cirrhosis of liver, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Not applicable | 2026-06-17 | NCT05486572 | |
| A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-06-04 | NCT03445559 | |
| VA Transitional Pain Service Study | Chemically-Induced Disorders, Narcotic-Related Disorders, Neurologic Manifestations, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Pain, Signs and Symptoms, opiate dependence, psychiatric disorder, substance-related disorder | Recruiting | Not applicable | 2026-05-06 | NCT06223503 | |
| Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response | Back Pain, Low Back Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Not applicable | 2026-05-04 | NCT04142177 | |
| Novel Approaches for Improving Vascular Function in Veterans With HFpEF | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 1 | 2026-04-23 | NCT06312748 | |
| Muscle Blood Flow Regulation in HFpEF | HFpEF | Recruiting | Not applicable | 2026-04-21 | NCT05115890 | |
| Pentoxifylline in Diabetic Kidney Disease | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, diabetes mellitus, diabetic kidney disease, endocrine system disorder, kidney disorder, urinary system disorder | Active, not recruiting | Phase 4 | 2026-04-13 | NCT03625648 | |
| Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout | Arthritis, Gouty, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Nutritional and Metabolic Diseases, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Not yet recruiting | Not applicable | 2026-02-19 | NCT06887452 | |
| Randomized Trial of SGLT2i in Heart Transplant Recipients | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, cardiovascular disorder, kidney disorder, urinary system disorder | Recruiting | Phase 4 | 2026-01-22 | NCT06625073 | |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Arterial Occlusive Diseases, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, metabolic disease, myocardial ischemia, nervous system disorder, peripheral arterial disease, peripheral vascular disease, prediabetes syndrome, vascular disorder | Recruiting | Phase 4 | 2025-12-17 | NCT02915198 | |
| Stellate Ganglion Block for PTSD | Stress Disorders, Traumatic, acute stress disorder, post-traumatic stress disorder, psychiatric disorder | Active, not recruiting | Not applicable | 2025-12-03 | NCT05169190 | |
| Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation | cardiovascular disorder | Active, not recruiting | Not stated | 2025-12-03 | NCT03625349 | |
| Ca-Mg Butyrate in GWI | Cognition Disorders, cognitive disorder, psychiatric disorder | Recruiting | Phase 2 | 2025-10-31 | NCT05367245 |